EUACCBack to showcase
NC BIOMATRIX

NC BIOMATRIX

Grant-FundedCORDIS

Injectable biomaterial gel for spinal disc degeneration treatment

Visit website
Digital Health · Biotech
Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs. Current treatments are only symptomatic (physiotherapy, pain management or surgery), but they do not regenerate the disc and its function. At NC Biomatrix, we have developed VitaDisc, the first non-invasive early restorative treatment for disc degeneration that has the power to revolutionise the orthopaedics market. It is an acellular porcine-derived injectable biomatrix that restores disc height, provides optimal support to regenerate the disc, and aids in restoring healthy spinal biomechanics. Its mode of action is fully mechanical, and it can be easily administered in an outpatient setting, giving it a unique market advantage. Our biomatrix platform technology is readily scalable and provides a pipeline of further products for unmet needs in orthopaedic treatments, such as early-stage knee joint arthritis.
EU Grants€2.5M
Open to funding

Team

PK

Prof Keita Ito

Founder

All-time revenue
MRRPrivate••••••
FounderProf Keita Ito
Founded2019
🇳🇱Netherlands
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics

Startup insights

Business detailsB2B
Digital HealthBiotech
Tags:Digital HealthBiotech
Looking for:InvestmentPartnerships